. 2019 Mar 26;321(12):1216–1217. doi: 10.1001/jama.2019.0441

Table. Protocol Characteristics for Generalized Convulsive Status Epilepticus in Adults Treated at Emergency Medical Services Systems in California.

Protocol Characteristics	No. (%) (N = 33)
Updated after December 31, 2012^a	27 (81.8)
Updated after December 31, 2016^b	17 (51.5)
Defined generalized convulsive status epilepticus according to AES or ILAE guidelines^c	7 (21.2)
Midazolam, intramuscular	32 (97.0)
Dose matches guidelines^d	2 (6.1)
Lorazepam, intravenous	2 (6.1)
Dose matches guidelines^e	2 (6.1)
Diazepam, intravenous	5 (15.2)
Dose matches guidelines^f	2 (6.1)
Recommended ≥1 medications by route and dose suggested in trials or guidelines	6 (18.2)

Abbreviations: AES, American Epilepsy Society; ILAE, International League Against Epilepsy.

^{^a}

The 2 randomized clinical trials were published in 2001 (Prehospital Treatment of Status Epilepticus trial; PHTSE) and 2012 (Rapid Anticonvulsant Medication Prior to Arrival Trial; RAMPART).

^{^b}

The AES guideline was published in 2016.

^{^c}

Definitions include 5 minutes or more of continuous seizure or 2 or more discrete seizures between which there is incomplete recovery of consciousness.^3,4

^{^d}

RAMPART and AES guideline recommend 10 mg administered intramuscularly in adults who weigh more than 40 kg.

^{^e}

PHTSE trial¹ recommends 2 mg administered intravenously (may repeat once); RAMPART,² 4 mg intravenously once.

^{^f}

PHTSE trial¹ recommends 5 mg administered intravenously (may repeat once); AES guideline,³ 0.15-0.2 mg/kg/dose, maximum of 10 mg/dose, may repeat once.